J&J Gains Phase III Oral Anti-Thrombotic Agent Under Bayer Collaboration
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bayer is highlighting Johnson & Johnson's track record in developing novel cardiovascular drugs as a key asset in a co-development pact for its anti-thrombotic agent BAY 59-7939, announced Oct. 26